FDA Targets Online Ketamine Sellers As Safety Concerns Grow
The FDA’s latest ketamine action is not aimed at a licensed clinic or a supervised treatment program. It is aimed at a far riskier corner of the market: websites selling unapproved ketamine products directly to consumers.
In a new warning letter, the agency said one online seller offered ketamine and esketamine products without FDA approval, without adequate directions for safe use and without the safeguards that prescription drugs require. The message is narrow, but the larger warning is clear. As interest in ketamine grows, regulators are watching how it is sold.
Do you run a ketamine clinic? HealingMaps has launched the first Group Purchasing Organization built for the ketamine industry — and it’s free to join. Members get 40%+ off medical supplies, discounted professional liability and medmal insurance for ketamine practitioners, LegitScript certification at a reduced rate, and HIPAA-compliant credit card processing. There’s zero cost or obligation to become a member.
→ healinghealthalliance.com/contact
An Overview
| Key takeaway | What it means |
|---|---|
| FDA is targeting illicit online sellers | The warning focused on unapproved ketamine products sold online. |
| Ketamine is not FDA approved for psychiatric disorders | FDA approved ketamine is an anesthetic, not a depression treatment. |
| Spravato is different | Esketamine nasal spray is FDA approved under strict REMS controls. |
| Online access can create real risks | Products may be contaminated, counterfeit or incorrectly dosed. |
| Supervision matters | Ketamine carries risks that require medical screening and monitoring. |
Looking for treatment? Find Spravato clinics (which is covered by insurance) and ketamine clinics closest to you as well as other psychedelic therapies in your area.
Why This Warning Matters
Ketamine sits in a complicated place in medicine. It is an FDA approved anesthetic and a Schedule III controlled substance. Clinicians may also use it off label in carefully monitored settings.
That is very different from buying ketamine from a website that offers it like an ordinary online product.
The FDA letter focused on products marketed as ketamine and ketamine nasal spray. The agency said the seller made treatment claims for pain and mental health conditions, including treatment resistant depression and anxiety.
Those claims matter because they turn a product into a drug under federal law. Once that happens, FDA approval, labeling rules and prescription safeguards apply.
The Difference Between Clinical Care And Online Sales
The warning does not say all ketamine treatment is illegal. It does not change the fact that some clinicians use ketamine off label for depression, pain or trauma related conditions.
The issue is how the product reaches the patient.
In a clinical setting, patients should be screened. Blood pressure, psychiatric history, substance use risk and medication interactions should be reviewed. During treatment, patients may need monitoring for dissociation, sedation and vital sign changes.
An illicit online seller does not offer that structure. A checkout page cannot evaluate risk. It cannot monitor a patient after dosing. It cannot confirm product quality in the way regulated systems are designed to do.
Why Spravato Keeps Coming Up
The FDA also drew a line around Spravato, the approved esketamine nasal spray. Spravato is approved for certain adults with treatment resistant depression and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior.
But it is not sent home for casual use. It is available only through a restricted safety program. Patients receive it in certified medical settings and are monitored afterward.
That comparison matters. If the approved nasal spray requires tight controls, regulators are unlikely to ignore unapproved nasal products sold online with fewer safeguards.
What Patients Should Look For
A safe ketamine pathway should feel like medical care, not online shopping.
Look for a licensed prescriber, clear screening, transparent pharmacy information and specific instructions for monitoring. Be cautious of any seller that promises easy access, broad mental health benefits or prescription drugs without a real evaluation.
The FDA’s warning is not just about one website. It is about the gap between legitimate care and a market trying to sell ketamine without the guardrails. As demand rises, that gap is becoming harder for regulators to ignore.
